OPEXA THERAPEUTICS
Updated 45 days ago
2635 Technology Forest Blvd. The Woodlands, TX 77381
Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publically traded biotechnology company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as Neuromyelitis Optica (NMO). These therapies are based on Opexa's proprietary T-cell technology, ImmPath®. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS.
Also known as: Opexa Therapeutics, Inc.